跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 27 条关于
“KCNJ13”
全部
27
临床试验
13
药物
7
机构
0
资讯
7
去年
Hubble Therapeutics Secures $7.3M Series A Funding for Gene Therapy Targeting Rare Childhood Blindness
去年
Cerevance Reports Positive Phase 1 Results for Novel KCNK13 Inhibitor CVN293 Targeting Neuroinflammation
3天前
Jazz Pharmaceuticals Completes $820M Actio Biosciences Acquisition, Adding First-in-Class KCNT1 Epilepsy Candidate ABS-1230
去年
Actio Biosciences Receives FDA Clearance and Fast Track Designation for First-in-Class KCNT1 Epilepsy Treatment
28天前
Eight-month-old becomes first in world to receive precision medicine for KCNT1-related catastrophic epilepsy
3个月前
Servier Enrolls First Patient in Phase Ib/II Trial of ASO Therapy for KCNT1-Related Pediatric Epilepsy
上个月
Jazz Pharmaceuticals to Acquire Actio Biosciences for $820 Million, Securing First-in-Class KCNT1 Epilepsy Therapy ABS-1230